Retrophin names Stepehen Aselage CEO
This article was originally published in Scrip
Executive Summary
Retrophin, a privately held biotechnology company focused on rare diseases, has named Stephen Aselage as its new CEO. He joins from BioMarin Pharmaceutical where he was chief business officer.